Tuesday, February 7, 2023
No Result
View All Result
  • Media
Support Us
Macdonald-Laurier Institute
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Energy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Energy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media
No Result
View All Result
Macdonald-Laurier Institute

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

Canadians with rare disorders continue to suffer from a lack of fair and timely access to innovative therapies.

January 24, 2023
in Columns, Domestic Policy Program, Health, In the Media, John Adams, Latest News, Nigel Rawson
Reading Time: 4 mins read
A A
For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

Photo by Christina Victoria Craft on Unsplash.

This article originally appeared in the Financial Post.

By Nigel Rawson and John Adams, January 24, 2023

Forty years ago this month, the United States passed the Orphan Drug Act (ODA) to facilitate the development of drugs for rare disorders. This was an important political issue in the late 1970s and early 1980s because, although individual disorders impacted small numbers of patients, overall rare diseases affected 20-25 million people and most disorders had no treatment.

Rare means patient numbers are small, ranging from less than 100 to several thousand. Such numbers don’t make much of a business case for developing medicines. The ODA introduced incentives to stimulate research and development of small-market medicines, including tax credits for qualifying clinical trials, exemption from regulatory fees, and a potential seven years of market exclusivity after approval, regardless of patent or data protections.

The ODA has been successful in its objective. In 1983, only 38 drugs were approved in the United States specifically to treat orphan diseases. But between 1983 and 2019, more than 5,000 medicines were, with the number more than quadrupling between the 1990s and 2010s. In the last decade, the number of drugs available to treat rare diseases in children has increased markedly.

Canada has no orphan drug act nor any incentives to encourage drug developers to launch medicines for small numbers of patients. There is no national strategy to treat rare disorders, while at the provincial level, only Quebec has a plan for the care of individuals with rare diseases — which it introduced only last year. Other provinces have no plan — just piecemeal efforts for some patients to access some drugs. When a new costly rare-disorder drug is approved in Canada, public insurers’ first thought seems to be how to avoid paying for it.

Patient advocates, including the Canadian Organization for Rare Disorders (CORD), have attempted to get the federal government to implement a national plan. CORD proposed a strategy that included promoting innovative research and providing timely, evidence-based, sustainable access to promising therapies. But policy-makers failed to get on board.

In the 2019 federal budget, the Liberals did say they would introduce a strategy and in their 2021 election platform they promised $500 million per year to fund costly drugs for rare diseases. But the only action so far has been a Health Canada discussion paper. Canadian patients have yet to benefit from any funding.

What the federal government has done in the general area of therapeutic drugs is move backwards on sustainable access to promising therapies. Over the past seven years, it has tried to drastically cut drug prices — apparently without either realizing or caring that doing so would delay or deny access to new medicines. This disregard of likely harms to patients has sent a chilling message about Canada’s dismissive attitude to therapeutic innovation.

The result? Between 2006 and 2014, 80 per cent of medicines submitted for regulatory approval in the United States or the European Union were also submitted for regulatory approval in Canada but, by 2020, that number had decreased to just 44 percent. Corresponding figures for orphan drugs were similar: 79 per cent on average between 2006 and 2014 down to 39 per cent in 2020 When developers are discouraged from submitting new medicines for marketing authorization in Canada, the drugs won’t be available to any Canadian.

Marketing approval is just the first step in getting medicines to patients. Once approved, developers face more obstacles in Canada: unaccountable, non-independent and non-transparent health technology assessments performed by organizations making recommendations to the same governments that fund and manage them; an unaccountable and non-transparent price negotiation organization also responsible to the same governments; and officials working for these governments who have no motivation to add new drugs to public drug plan formularies.

Overcoming these hurdles usually takes years. Even when the costs of drugs are covered by government plans, restrictive patient access requirements are imposed to contain these costs, not improve health outcomes.

People suffering rare disorders are like all other Canadians — they want affordable access to medicines for their unmet health needs. But at the same time they don’t want access denied by Ottawa’s plans to force down drug prices to levels that are unsustainable for developers, who then decide the Canadian market isn’t worth bothering with. Canadians won’t have first-class access to biopharmaceutical innovation if their government only pays for a third-class ticket.

Four decades after the ODA was enacted, Canadians with rare disorders continue to suffer from a lack of fair and timely access to innovative therapies. They need many things but they especially need a law like the ODA to incentivize developers to launch rare-disorder medicines in Canada and provide early access to the many innovative treatments on the research horizon that can reduce suffering and improve and even save lives.

Nigel Rawson is an affiliate scholar with the Canadian Health Policy Institute and a senior fellow with the Macdonald-Laurier Institute, as is John Adams, co-founder and CEO of Canadian PKU and Allied Disorders Inc.

Source: Financial Post
Tags: Drug PriceshealthcareJohn AdamsNigel Rawson
Previous Post

Ford’s health plan will be good for patients, if he can get it past the unions: Shawn Whatley in the National Post

Next Post

Shutdown of talk at McGill threatens freedom of expression in Canada: Jamie Sarkonak for Inside Policy

Related Posts

Prioritizing gender identity over sex in prisons endangers female prisoners
Releases

Prioritizing gender identity over sex in prisons endangers female prisoners

February 6, 2023
Greedflation? It’s a government thing: Philip Cross in the Financial Post
Columns

Jagmeet Singh uses confusion about private care to support the status quo: Shawn Whatley in the National Post

February 6, 2023
Prioritizing gender identity over sex in prisons endangers female prisoners
Papers

Rights and wrongs: How gender self-identification policy places women at risk in prison

February 6, 2023
Next Post
Shutdown of talk at McGill threatens freedom of expression in Canada: Jamie Sarkonak for Inside Policy

Shutdown of talk at McGill threatens freedom of expression in Canada: Jamie Sarkonak for Inside Policy

Macdonald-Laurier Institute

323 Chapel Street, Suite #300
Ottawa, Ontario
K1N 7Z2 Canada

613.482.8327

info@macdonaldlaurier.ca
MLI directory

Follow us on

Newsletter Signup

First Name
Last Name
Email Address

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

Inside Policy Magazine

  • Current Issue
  • Back Issues
  • Advertising
  • Inside Policy Blog
  • Privacy Policy

© 2021 Macdonald-Laurier Institute. All Rights reserved.

No Result
View All Result
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Energy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media

© 2021 Macdonald-Laurier Institute. All Rights reserved.

IDEAS CHANGE THE WORLD!Have the latest Canadian thought leadership delivered straight to your inbox.
First Name
Last Name
Email address

No thanks, I’m not interested.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Privacy Preference Center

Consent Management

Necessary

Advertising

Analytics

Other